Tecartus (brexucabtagene autoleucel) / Gilead, Fosun Kite - LARVOL DELTA

Gilead Sciences Announces First Quarter 2025 Financial Results (Businesswire) - "Cell Therapy product sales decreased 3% to $464 million in the first quarter 2025 compared to the same period in 2024. Yescarta (axicabtagene ciloleucel) sales increased 2% to $386 million in the first quarter 2025 compared to the same period in 2024, primarily driven by higher average realized price and increased rest of world demand, partially offset by lower demand in the United States. Tecartus (brexucabtagene autoleucel) sales decreased 22% to $78 million in the first quarter 2025 compared to the same period in 2024, primarily reflecting lower demand in the United States."

Sales • Acute Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Mantle Cell Lymphoma

Case Report: Successful use of emapalumab in adult B-cell acute lymphoblastic leukemia experiencing severe neurotoxicity and hemophagocytic lymphohistiocytosis-like features after CAR-T cell therapy. (PubMed, Front Immunol) - "We report an adult B-cell acute lymphoblastic leukemia (B-ALL) patient treated with brexucabtagene autoleucel (brexu-cel)...Treatment included tocilizumab, high-dose corticosteroids, anakinra, siltuximab, and ruxolitinib...The patient recovered from IEC-HS and underwent allogeneic stem cell transplantation. This case highlights the role of emapalumab in managing refractory IEC-HS and persistent neurotoxicity in adults, underscoring the need for targeted interventions in severe CAR-T complications."

IO biomarker • Journal • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Leukemia • Oncology • Rare Diseases • Transplantation • IFNG

Brexucabtagene autoleucel (Brexu-cel) as consolidation treatment in adults with B-cell acute lymphoblastic leukemia. (ASCO 2025) - "The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology

ZUMA-8: A Phase 1 Study of Brexucabtagene Autoleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia. (PubMed, Blood) - P1 | "Patients with ≥2 prior lines of therapy (including a BTK inhibitor) underwent leukapheresis, followed by optional bridging therapy, then conditioning chemotherapy (fludarabine/cyclophosphamide) before infusing 1×106 (Cohort 1) or 2×106 (Cohort 2) anti-CD19 CAR T cells/kg. Patients in Cohort 3 (low tumor burden), and Cohort 4A (ibrutinib pre-treated closely to the apheresis) received 1×106 cells/kg...CAR T-cell expansion occurred in 4 patients (27%), with an apparent weak inverse correlation with absolute lymphocyte count (ALC) prior to the apheresis. Brexu-cel did not have any new safety signals in R/R CLL, and CAR T-cell expansion and responses occurred in patients with low tumor burden."

Journal • P1 data • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cells for B-Cell Lymphomas: An ILROG Multicenter Study. (PubMed, Blood Adv) - "172 patients (168 large BCL, 3 mantle cell, 1 Burkitt) received Br-RT prior to axicabtagene ciloleucel (73%), tisagenlecleucel (23%), or brexucabtagene autoleucel (2%). In this particularly high-risk cohort, Br-RT prior to CAR-T demonstrates an acceptable toxicity profile with favorable clinical outcomes when compared to historical controls. Comprehensive Br-RT and LDH normalization post-Br-RT may be associated with superior PFS and OS."

Clinical • Journal • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

SEIZURE PROPHYLAXIS WITH CAR-T PRODUCTS – A SURVEY OF UK PRACTICE (EBMT 2025) - "Background: Kymriah® (tisagenlecleucel), Yescarta® (axicabtagene ciloleucel) and Tecartus® (brexucabtagene autoleucel) are the licensed chimeric antigen receptor T-cells (CAR-T) products in the UK. There is a significant variation in levetiracetam use for all surveyed cancer centres. Many of them adjust levetiracetam dosing based on individual patient's risk factors and complications post-CAR-T administration. Two limitations to this survey were the poor quality of responses from some survey participants and the difference in using Kymriah® for DLBCL between UK nations due to the NICE appraisal termination in 2023."

CNS Disorders • Diffuse Large B Cell Lymphoma • Epilepsy • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Immunology • Lymphoma • Oncology • Pediatrics • Vascular Neurology

LYMPHODEPLETION WITH SINGLE AGENT BENDAMUSTINE PRIOR TO CAR T-CELL THERAPY IN PATIENTS WITH IMPAIRED RENAL FUNCTION (EBMT 2025) - "Background: Chimeric antigen receptor T-cell therapy (CART) leads to high rates of remission in patients with aggressive lymphomas (NHL) and multiple myeloma (MM) and is commonly applied following lymphodepletion (LD) with fludarabine and cyclophosphamide... 10 patients (50% female) received bendamustine for LD prior to CART in real-world setting (ciltacabtagene-autoleucel N=7, lisocabtagene maraleucel N=1, brexucabtagene autoleucel N=1, axicabtagene ciloleucel N=1)... In our cohort, 2/7 patients with in-specification CART products showed no expansion of CAR T-cells. In contrast, 3/3 patients with OOS products had sufficient expansion of CAR T-cells and responded to treatment. Further studies are warranted to determine the role bendamustine in LD prior to CART patients with chronic kidney injury."

CAR T-Cell Therapy • Clinical • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Multiple Myeloma • Nephrology • Oncology • Pneumonia • Renal Disease • Respiratory Diseases • IFNG

CAR-T CELL RECEPTOR ASSOCIATED TREMOR - AN OBSERVATIONAL STUDY (EBMT 2025) - "One presented with mantle cell lymphoma treated with Tecartus and other three, have DLBCL treated with Yescarta...One patient was also treated with low-dose clonazepam, which provided additional relief... Our findings highlight the significance of CAR T cell receptor associated tremor as a neurotoxic complication in patients undergoing CAR-T therapy. The temporal relationship between CAR-T infusion, ICANS and the onset of tremor suggests a potential link to the neuroinflammatory processes triggered by the therapy. While the pathophysiology remains to be fully elucidated, our observations underscore the importance of close monitoring, enabling timely interventions and supportive care."

CAR T-Cell Therapy • Clinical • Observational data • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Movement Disorders • Oncology

CAR-T CELL RECEPTOR ASSOCIATED TREMOR - AN OBSERVATIONAL STUDY (EBMT 2025) - "One presented with mantle cell lymphoma treated with Tecartus and other three, have DLBCL treated with Yescarta...One patient was also treated with low-dose clonazepam, which provided additional relief... Our findings highlight the significance of CAR T cell receptor associated tremor as a neurotoxic complication in patients undergoing CAR-T therapy. The temporal relationship between CAR-T infusion, ICANS and the onset of tremor suggests a potential link to the neuroinflammatory processes triggered by the therapy. While the pathophysiology remains to be fully elucidated, our observations underscore the importance of close monitoring, enabling timely interventions and supportive care."

CAR T-Cell Therapy • Clinical • Observational data • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Movement Disorders • Oncology

LYMPHODEPLETION WITH SINGLE AGENT BENDAMUSTINE PRIOR TO CAR T-CELL THERAPY IN PATIENTS WITH IMPAIRED RENAL FUNCTION (EBMT 2025) - "Background: Chimeric antigen receptor T-cell therapy (CART) leads to high rates of remission in patients with aggressive lymphomas (NHL) and multiple myeloma (MM) and is commonly applied following lymphodepletion (LD) with fludarabine and cyclophosphamide... 10 patients (50% female) received bendamustine for LD prior to CART in real-world setting (ciltacabtagene-autoleucel N=7, lisocabtagene maraleucel N=1, brexucabtagene autoleucel N=1, axicabtagene ciloleucel N=1)... In our cohort, 2/7 patients with in-specification CART products showed no expansion of CAR T-cells. In contrast, 3/3 patients with OOS products had sufficient expansion of CAR T-cells and responded to treatment. Further studies are warranted to determine the role bendamustine in LD prior to CART patients with chronic kidney injury."

CAR T-Cell Therapy • Clinical • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Multiple Myeloma • Nephrology • Oncology • Pneumonia • Renal Disease • Respiratory Diseases • IFNG

CAR-T CELL DYNAMICS AND MYELOID-CELL ALTERED PROFILE ARE ASSOCIATED WITH CLINICAL OUTCOME IN ANTI-CD19 CAR-T CELL THERAPY FOR RELAPSED/REFRACTORY B-CELL MALIGNANCIES: A REAL-LIFE COHORT STUDY (EBMT 2025) - "Twenty patients received axicabtagene ciloleucel (axi-cel), 9 brexucabtagene autoleucel (brexu-cel) and 18 tisagenlecleucel (tisa-cel). These results indicate the presence of immunological biomarkers within IP, the amount and clonality of circulating CAR-T, and myeloid cell phenotype that can predict clinical outcomes, including the susceptibility to develop severe toxicities."

CAR T-Cell Therapy • Clinical • Clinical data • IO biomarker • Acute Lymphocytic Leukemia • B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD163 • CD86

Advancing Equity in CAR T-Cell Therapy: An Analysis of Health Technology Assessments by Canada's Drug Agency and the National Institute for Health and Care Excellence (ISPOR 2025) - "This review examines if and how health technology assessments (HTAs) by Canada's Drug Agency (CDA) and the National Institute for Health and Care Excellence (NICE) consider equity in evaluating CAR T-cell therapies. HTA reports from CDA and NICE for six CAR T-cell therapies (Abecma, Breyanzi, Carvykti, Kymriah, Tecartus, Yescarta) were reviewed by two researchers for equity considerations related to access disparities, capacity, socioeconomic determinants, and related clinical and economic evidence. This review identified that DEI considerations related to CAR T-cell therapy access like patient costs and geographical barriers were not routinely supported by evidence in CDA and NICE submissions. Evidence generation challenges in CAR-T therapy may inadvertently deprioritize equity concerns. Recent commitments to equity from HTA bodies offer opportunities to ensure fair access to novel, high-cost therapies."

CAR T-Cell Therapy • Reimbursement • US reimbursement • Hematological Disorders • Hematological Malignancies • Oncology

SURVEILLANCE AND PROPHYLAXIS OF INFECTIONS FOLLOWING CAR-T CELL THERAPY: INTERNATIONAL SURVEY ON BEHALF OF THE INFECTIOUS DISEASES WORKING PARTY AND GOCART COALITION EBMT (EBMT 2025) - "CAR-T products included tisagenlecleucel (89.4%), axicabtagene ciloleucel (84%), and brexucabtagene autoleucel (63.8%).Pre-CAR-T viral serology, recommended by guidelines (guidelines-recommended, GL-R), was performed in the following number of centers: CMV IgG, 90.6%; HIV antibody (Ab), 93.8%; Hepatitis B (anti-HBs-Ab/Ag, anti-HBc-Ab), 89.6%-93.8%; HCV-Ab, 88.5%; syphilis Ab, 74%; while non-GL-R EBV-Ab and CoVID-Ab anti-S/anti-N were performed in 82.3% and 26%/16.7%, respectively.Antibacterial (mainly fluoroquinolone) prophylaxis during neutropenia (not routinely GL-R, although can be considered in prolonged neutropenia), was given at 31/93 (33.3%) centers routinely and in 18/93 (19.4%) in specific situations, such as prolonged neutropenia (12 centers) and previous alloHCT (5 centers)...Anti-CMV prophylaxis (not GL-R) was given at 15/95 (15.8%) centers, mainly with high-dose acyclovir or letermovir.Guidelines recommend antifungal prophylaxis in patients with severe or..."

CAR T-Cell Therapy • Acute Lymphocytic Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Hepatitis B • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Leukemia • Lymphoma • Mantle Cell Lymphoma • Mediastinal B Cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Novel Coronavirus Disease • Oncology • Primary Mediastinal Large B-Cell Lymphoma

Diffusion and Launch Sequencing of Cell and Gene Therapies across the USA, Europe, Canada and Australia (ISPOR 2025) - "Only four products had positive HTA recommendations in all screened markets: Zolgensma, Luxturna, and Yescarta and Tecartus. Low rates of marketing authorisation and HTA approval have contributed to a fragmented access landscape for CGTs. While large firms may be better equipped to launch these technologies globally, high prices, uncertainties in clinical evidence, and technical complexities in administering therapies present continued barriers to uptake."

Gene therapy • Gene Therapies

Comparative Efficacy of Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion before Chimeric Antigen Receptor T-Cell Therapy in Lymphoma. (PubMed, Transplant Cell Ther) - "Bendamustine is a viable alternative to Flu/Cy for LDC prior to CAR-T therapy in relapsed/refractory NHL, as it demonstrates comparable efficacy and safety. Its operational advantages, including reduced hospitalization rates and suitability for outpatient administration, underscore its potential in diverse clinical settings. Prospective studies are needed to confirm long-term outcomes and further optimize LDC strategies."

Journal • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

FROM TUMOR BOARD DECISION TO INFUSION: ARE TIMELINES OF ANTI-CD19 DIRECTED CAR-T CELL THERAPY AFFECTING THE TREATMENT OUTCOME? (EBMT 2025) - "In 66 patients (86.8%) bridging therapy was recorded: rituximab, polatuzumab vedotin ± bendamustine (n=34), cytotoxic drugs (n=3), PI3K or TK inhibitors (n=9), antibodies (n=3), steroids (n=1), irradiation (n=4) or other treatments (n=12). Most patients received axicabtagene ciloleucel (n=35) or tisagenlecleucel (n=23), 4 patients received brexucabtagene autoleucel and 3 patient lisocabtagene ciloleucel... The median brain-to-vein time in our study was 69 days, aligning with recently published European data (Bücklein et al., 2024). In our patient cohort, OS did not significantly differ between those who received CAR-T cell infusion earlier (<42 days) or later. However, the results do not allow to assess the impact of bridging therapy and kind of drugs used on response and OS."

CAR T-Cell Therapy • Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

EFFICACY OF CAR-T CELL THERAPY AND PROGNOSTIC FACTOR ANALYSIS FOR RELAPSED/REFRACTORY B-NHL: A SINGLE CENTRE REAL LIFE EXPERIENCE (EBMT 2025) - "For patients with DLBCL, median number of bridging treatments was 2 (0-3) with dexamethasone being the most frequent one (53%), followed by R-GEMOX (41%) and Pola-BR (29%). Both axicabtagene ciloleucel for FL/DLBCL 3rd line and brexucabtagene autoleucel for r/r MCL represent a revolutionary treatment with excellent outcome for patients who would otherwise have dismal prognosis. However, our experience in DLBCL 2nd line is inferior to reported results. Age and PS at referral may aid optimal patient selection."

Biomarker • CAR T-Cell Therapy • Clinical • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Infectious Disease • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma

SURVEILLANCE AND PROPHYLAXIS OF INFECTIONS FOLLOWING CAR-T CELL THERAPY: INTERNATIONAL SURVEY ON BEHALF OF THE INFECTIOUS DISEASES WORKING PARTY AND GOCART COALITION EBMT (EBMT 2025) - "CAR-T products included tisagenlecleucel (89.4%), axicabtagene ciloleucel (84%), and brexucabtagene autoleucel (63.8%).Pre-CAR-T viral serology, recommended by guidelines (guidelines-recommended, GL-R), was performed in the following number of centers: CMV IgG, 90.6%; HIV antibody (Ab), 93.8%; Hepatitis B (anti-HBs-Ab/Ag, anti-HBc-Ab), 89.6%-93.8%; HCV-Ab, 88.5%; syphilis Ab, 74%; while non-GL-R EBV-Ab and CoVID-Ab anti-S/anti-N were performed in 82.3% and 26%/16.7%, respectively.Antibacterial (mainly fluoroquinolone) prophylaxis during neutropenia (not routinely GL-R, although can be considered in prolonged neutropenia), was given at 31/93 (33.3%) centers routinely and in 18/93 (19.4%) in specific situations, such as prolonged neutropenia (12 centers) and previous alloHCT (5 centers)...Anti-CMV prophylaxis (not GL-R) was given at 15/95 (15.8%) centers, mainly with high-dose acyclovir or letermovir.Guidelines recommend antifungal prophylaxis in patients with severe or..."

CAR T-Cell Therapy • Acute Lymphocytic Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Hepatitis B • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Leukemia • Lymphoma • Mantle Cell Lymphoma • Mediastinal B Cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Novel Coronavirus Disease • Oncology • Primary Mediastinal Large B-Cell Lymphoma

CAR T THERAPY IN SLOVAKIA: A SINGLE CENTRE EXPERIENCE (EBMT 2025) - "The first CAR T-cell centre for the treatment with tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel), and brexucabtagene autoleucel (brexu-cel) in Slovakia was certified in 2023. This single-centre experience with CAR T-cell therapy supports real-world data from other countries. Despite the short follow-up, our findings confirm a significant clinical benefit for some patients who have exhausted conventional therapeutic modalities."

Clinical • B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Large B Cell Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

Establishing best practice in the Australian haematology setting for the use of chimeric antigen receptor T-cell therapy for relapsed and refractory lymphoma. (PubMed, Intern Med J) - "In this review, we aim to define best practice for the referral and treatment of patients with R/R B-cell lymphoma with CAR T-cell therapy in Australia. We outline the processes for referral, optimal patient selection and best practice in the management of patients receiving CAR T cells."

Journal • Review • B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

EVALUATION OF COGNITIVE IMPAIRMENT AND NEUROTOXIC EFFECTS IN ADULT PATIENTS UNDERGOING CAR-T CELL THERAPY (EBMT 2025) - "Axicabtagene Ciloleucel was infused to 20 patients, Brexucabtagene Autoleucel to 4 patients, Tisagenlecleucel to 2 patients, Cilta-cel to 2 patients and PHE 885 to 2 patients according to disease indications. The lowest scores were identified 3 months after infusion irrespective of disease response or severe toxicities, indicating that further long-term studies are needed in this population."

CAR T-Cell Therapy • Clinical • Alzheimer's Disease • Cognitive Disorders • Hematological Malignancies • Oncology

MT2017-45: CAR-T Cell Therapy for Heme Malignancies (clinicaltrials.gov) - P2 | N=144 | Active, not recruiting | Sponsor: Masonic Cancer Center, University of Minnesota | Phase classification: P ➔ P2

Phase classification • Acute Lymphocytic Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Large B Cell Lymphoma • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • CD19

CAR-T CELL DYNAMICS AND MYELOID-CELL ALTERED PROFILE ARE ASSOCIATED WITH CLINICAL OUTCOME IN ANTI-CD19 CAR-T CELL THERAPY FOR RELAPSED/REFRACTORY B-CELL MALIGNANCIES: A REAL-LIFE COHORT STUDY (EBMT 2025) - "Twenty patients received axicabtagene ciloleucel (axi-cel), 9 brexucabtagene autoleucel (brexu-cel) and 18 tisagenlecleucel (tisa-cel). These results indicate the presence of immunological biomarkers within IP, the amount and clonality of circulating CAR-T, and myeloid cell phenotype that can predict clinical outcomes, including the susceptibility to develop severe toxicities."

CAR T-Cell Therapy • Clinical • Clinical data • IO biomarker • Acute Lymphocytic Leukemia • B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD163 • CD86

REAL WORLD INCIDENCE AND CHARACTERISTICS OF IMMUNE EFFECTOR CELL–ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTICYTOSIS: A GOCART COALITION STUDY ON BEHALF OF THE EBMT ADWP, CTIWP AND TCWP (EBMT 2025) - "Secondary HLH occurred in 12 patients treated with tisagenlecleucel (42.9%), 10 with axicabtagene ciloleucel (35.7%), 4 with brexucabtagene autoleucel (14.3%), and 2 treated with other products (7.2%). This registry study reported an incidence of 3.6% of sHLH post CAR-T at 90 days. Patients experienced heterogeneous clinical manifestations, mainly represented by fever and liver involvement. Anakinra and steroids represented the employed treatments and the overall survival was 80.9% at 90 days."

Clinical • IO biomarker • Real-world • Real-world evidence • B Cell Lymphoma • Bone Marrow Transplantation • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A SINGLE-CENTRE STUDY ON LONGITUDINAL CHANGES IN QUALITY OF LIFE AFTER CAR-T THERAPY IN PATIENTS WITH NON-HODGKIN LYMPHOMA (EBMT 2025) - "Between December 2019 and November 2024, 58 patients received one of the following CAR-T products: axicabtagene ciloleucel (n=50), tisagenlecleucel (n=6), or brexucabtagene autoleucel (n=2).Patients completed the Functional Assessment of Cancer Therapy – Lymphoma (FACT-Lym) questionnaire in person at baseline (prior to CAR-T therapy), at 30 days (discharge), 3 months, 6 months, and 12 months post-treatment. Over 12 months following CAR-T therapy, patients experienced an overall improvement in quality of life, encompassing physical, social/family, emotional, and functional well-being. Emotional well-being showed earlier improvement, while functional well-being only reached statistical significance at 12 months.Reduced compliance to questionnaires was primarily due to refusal at baseline and day 30, shifting to disease relapse from 3 months onward. Additional factors included the absence of a clinical nurse specialist and the reliance on virtual or telephone..."

Clinical • HEOR • Acute Lymphocytic Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Mantle Cell Lymphoma • Mediastinal B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma